Engineered immune cells take on recurrent head and neck cancer

NCT ID NCT06096038

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dose and to see if the treatment can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iC9-CAR.CSPG4 T cells (a type of CAR T-cell therapy)
What this could lead to: If successful, this could lead to a new treatment option for patients with head and neck cancer that has returned after standard therapy.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply to everyone. The treatment can cause serious side effects like cytokine release syndrome and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma neoplasm Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER RECURRENT REFRACTORY CANCER RELAPSE

Contacts and locations

Locations

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.